Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Credit Rating
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ICRA has reaffirmed Akums Drugs & Pharmaceuticals Limited's credit rating at ICRA AA (Stable)/A1+ for its long-term/short-term working capital facilities worth Rs. 85 crore. Additionally, ICRA assigned a new rating of ICRA A1+ for the company's proposed Commercial Paper Programme of Rs. 200 crore. The company continues to maintain a strong financial profile with cash and cash equivalents of Rs. 1,654.4 crore and total debt of only Rs. 90.3 crore as of September 30, 2025. The company generated revenues of Rs. 3,201.1 crore in 9M FY2026 with 7% YoY growth, driven by its CDMO business which includes a EUR 200 million contract with a European customer.
The reaffirmed AA (Stable) rating with stable outlook signals continued creditworthiness and stable business operations. The new commercial paper programme rating reflects the company's strong liquidity position and low reliance on external debt, which is positive for shareholders.